Two drug­mak­ers hit with PDU­FA date de­lays from FDA amid back­log of in­spec­tions

As the FDA is weighed down with more and more pan­dem­ic re­spon­si­bil­i­ties, the agency is be­gin­ning to miss PDU­FA dates with more fre­quen­cy too. Two dif­fer­ent com­pa­nies on Mon­day said they re­ceived no­tices that the FDA has not com­plet­ed their drug re­views on time.

The re­view of an NDA for Avadel Phar­ma­ceu­ti­cals’ can­di­date treat­ment for nar­colep­sy is not com­ing this month, the com­pa­ny said, and the re­view of UCB’s BLA for bimek­izum­ab, used to treat mod­er­ate to se­vere plaque pso­ri­a­sis, will miss its tar­get date as well.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER